Life Sciences Real Estate Forum
Dana Point, CA
November 4 - 5, 2021

Description

After the success of our virtual event in May, IMN is pleased to announce the in-person launch of the Life Sciences Real Estate Forum, the first and only national conference to explore the range of investment and development opportunities in life sciences real estate.

The global pandemic has catalyzed investment in life sciences, biotech and pharma (over $45 billion of venture capital entered the sector in 2020) but these sectors remain significantly undersupplied from a real estate perspective. Last year saw a 12 percent increase in total commercial lab space to 95 million square feet, and with more than 35 million square feet of new construction in the pipeline, complemented by increased property conversions into lab spaces, this forum is the perfect place to learn and meet incumbent leaders and new players in this exciting sector.

Conveniently located between the established life science hubs of San Diego and Los Angeles, the event is hosted against Southern California’s pristine setting of Dana Point. With a plethora of on-site learning and networking opportunities, the location provides an ideal assembly point for national and local investors, developers, life science/biotech/pharma companies, lenders, brokers and other real estate professionals to do business.

Provisional topics include:
  • Technical considerations for designing, constructing & operating life science facilities
  • Development opportunities in pharmaceutical office, lab, incubator, cold storage and mixed-use
  • The impact of drug discovery and vaccine development on life sciences real estate innovation
  • Financing life sciences real estate investments; sourcing government, institutional, VC, and alternative funding
  • Emerging market outlook, JV and public-private partnership structures, institutional fund flows
  • Conversion & adaptive reuse opportunities and incentives
  • Property management & leasing strategies
  • Innovation Districts

Of course the health and safety of our staff, our customers and indeed all our stakeholders is of paramount importance to us.  To that end we will continue to work closely with our event execution partners to ensure we welcome you safely and deliver a legally compliant and best-in-class experience for you all.  We will follow local government guidelines and incorporate measures outlined in the Euromoney Events Shield to ensure optimal health and sanitary conditions are maintained throughout the event.

We look forward to seeing you this November in Dana Point, CA!

Conference Highlights

Networking Tutorial

    Platform Introduction
    LOADING MEDIA...
    Getting Started
    LOADING MEDIA...
    Updating Personal Info
    LOADING MEDIA...
    Updating Demographics
    LOADING MEDIA...
    Searching By Name/Company
    LOADING MEDIA...
    Filter By Demographics
    LOADING MEDIA...
    Send Invitation
    LOADING MEDIA...
    Accept Invitation
    LOADING MEDIA...
    Messaging Connections
    LOADING MEDIA...
    Post Conference Content
    LOADING MEDIA...

My Agenda

  • To view your agenda you must be signed in Sign-In

Agenda

    Preliminary Agenda

      Macroeconomic Factors Accelerating Growth of Life Science

        • Outside of core markets, which submarkets are experiencing the highest demand for life sciences real estate facilities?
        • How does the development pipeline differ for the fastest-growing markets?
        • What impact will advancements in drug discovery and development have on transaction volume and sector demand?
        • Which regulatory changes could pose new risks and expand opportunities in the sector?


      Life Sciences Real Estate Investment Strategies

        • By submarket and property subtype, where are institutional and high-net-worth investors, family offices, pension and sovereign wealth funds looking to unlock value?
        • How do valuation methodologies differ from other industrial and office property types?
        • How are middle-market investors using JVs to capture deal flow?
        • How are investors in life sciences companies approaching decisions on portfolio diversity and risk-reward premium? What kinds of companies are they targeting?
        • Which tools are investors using to improve data analysis, underwriting, portfolio and asset management of life science real estate assets?


      Financing Complex Life Sciences Real Estate Transactions

        • Who is financing new construction, and what terms are available?
        • What returns are private equity investors requiring to provide financing?
        • Which areas of pharmaceutical research are drawing the most demand from private equity investors?
        • How are governments and municipalities filling gaps in financing? Which groups are offering the most attractive financing options? What makes them appealing to investors?


      Construction & Development of Facilities & Campuses

        • How do construction costs compare to traditional industrial and office properties?
        • What are general contractors seeing in terms of lead times on equipment?
        • Which submarkets are likely to offer the highest returns for ground-up development?
        • Which debt, equity, and other financial incentives are available for construction and adaptive reuse? How can these sources be combined to alleviate the cost burden of constructing life sciences facilities and campuses?
        • What are the newest innovations in sustainable building materials, such as mass timber, and how are developers incorporating these into their life science projects?
        • Which technologies are providing efficiencies in construction project and workflow management, scheduling, budgeting and communications?


      Investing in Technology to Improve Property Management, Leasing & Design

        • What features are being implemented to attract tenants and offer a unique tenant experience?
        • How are life sciences facilities using automation, access control technology and other PropTech to optimize building performance and safety?
        • What type of physical infrastructure is required to build life sciences facilities?
        • What should these facilities be located, in relation to population centers, transit hubs, and additional developable land?
        • How do space needs differ across tenants in various sectors, including pharmaceutical research, biotech, genomics and genetics, and biomedical devices?
        • What kids of architect and design partners do real estate developers need to engage, and what degree of expertise is needed, to meet the complex requirements of designing life sciences facilities?


      Disruptors & Drivers of Long-Term Growth in Life Sciences Real Estate

        • Which secondary and tertiary markets are leading in life sciences real estate investment growth?
        • Which creative partnership structures are emerging in this space? How are middle-market investors using JVs to capture deal flow?
        • What do new construction and development fundamentals look like in emerging markets, and which groups are most active?
        • Where are the next opportunities for innovation and disruption in the sector? Which new players have entered the space recently? Which new strategies are you looking to deploy around life sciences real estate?


      Incubators, Accelerators & Co-Working Lab Space

        • Why are incubators and accelerators so crucial for innovation within the industry?
        • How do incubators attract and retain tenants?
        • Where are the biggest markets and which markets are they expanding into?
        • Who are the tenants?  How are the needs of tenants changing?
        • What considerations are needed when designing co-working lab space?
        • How do you manage the relationship with the developer?


      Adaptive Reuse in Life Sciences Projects

        • What challenges are there with repositioning a property for life sciences?
        • Which functional systems are essential for different lab/office types?  How are these implemented?
        • Case studies of industrial, office and other commercial buildings being converted for life sciences use
        • Creative financing solutions for adaptive reuse
        • Timeframe necessary for repositioning


      Opportunity Zones & Life Sciences

        • Overview of opportunity zone provisions, following the most recent guidance
        • How do opportunity zone funds fit into your long-term investment strategy and fund structure?
        • Structuring and re-structuring deals to leverage valuable tax benefits
        • Development fees and eligibility of ground leases
        • Due diligence on opportunity zone projects and analyzing the merits of the project without the added tax benefits


      “Collaborate to Compete”: Evaluating the Role of Innovation Districts in Life Sciences Growth

        • What are innovation districts and why are they important to life sciences?
        • How are they financed?
        • Why are innovation districts ideal platforms for economic recovery post-COVID?
        • Non-traditional players entering the life sciences space through innovation districts
        • How can life sciences companies and real estate players help create economic and social benefits?


      Designing the Life Science Facilities of Today and Tomorrow

        • How can the way in which facilities are designed drive innovation?
        • Vertical vs. horizontal: using space creatively in dense urban areas
        • How to ensure facility adaptability and flexibility for a variety of operators and tenants
        • Essential features and systems vs. ‘nice to have’
        • Efficiently incorporating space for incubator/accelerators, graduation, R&D and manufacturing
        • GMP considerations
        • What are the biggest challenges in designing today’s facilities based on tenant requirements?


      R&D Investment: Exploring Advancements in Biotech

        • What exciting innovations are coming down the pike?
        • Where are most investment dollars going currently?
        • Tenant requirement implications for landlords
        • How can the sector further embrace public-private partnerships (P3) for R&D?
        • What main challenges are companies facing that impede R&D?


      Disposition & Exit Strategies

        • When making an acquisition, what exit considerations are taken?
        • What are the factors that infer decisions on exit timings?
        • What are the primary disposition options available?
        • How do these options vary across property types?
        • Differences between selling individual assets and portfolios or campuses


      Assessing the Pros & Cons of Joint Venture Projects

        • How to identify the right partner for a JV deal in life sciences
        • Do you look for partners in specific markets?
        • Are JVs better suited to individual properties or portfolios?
        • Structures, terms and items that take the most negotiating
        • Risk management within a JV structure
        • Planning an exit: short vs. long term


      SoCal Market Spotlight

        • What does current life science facility inventory look like?
        • What is in demand with local tenants?
        • Where are developments planned/underway?
        • Strategies for attracting a talented workforce to the area
        • What are the major challenges developing CRE for life sciences in SoCal?


      Life Science Facility Leasing & Management Best Practices

        • Optimizing the leasing process and lease administration
        • Strategies for attracting tenants and managing those relationships
        • Lease clauses that are typical to life sciences and may differ from other CRE leases
        • Who is responsible for building services and maintenance?
        • How can technology be utilized to reduce costs, improve efficiencies and mitigate risk?


      Good Manufacturing Practice (GMP) & Implications for Life Sciences Real Estate

        • Evaluating the various stages of mass-producing new therapies and products
        • How much GMP space is needed for various industries?  How does this change throughout the life cycle development?
        • Assessing credit risk
        • Where does GMP space need to be in relation to R&D space? Can it be outside the cluster?


Sponsors

Register

To register for this conference you must be signed in

  • *Life Sciences Company/Investor/Developer Early Bird Rate - $995
  • *Life Sciences Company/Investor/Developer Rate - $1,195
  • Early Bird Registration - $1,695
  • Standard Registration - $1,895
  • Virtual Events Registration - $595
Sign-In

Contact Us

Venue

  • Conference Venue
  • Waldorf Astoria Monarch Beach Resort & Club


    1 Monarch Beach Resort
    Dana Point, CA, 92629
    USA

    Additional Info:

    Please use the link above to book a room in IMN's block, pending availability, until our cutoff date of Wednesday, October 13. 

    IMPORTANT NOTE: IMN has not retained any third party booking company to assist with reservations. If you are interested in making reservations at Waldorf Astoria Monarch Beach Resort & Club, you must book those rooms directly with the venue. 

1120 Avenue of the Americas, 6th Floor, New York, NY 10036
Tel: +1(212)901-0506 Fax: +1(212)768-2484
Email: mail@imn.org


View Full Site
You need to login before accessing this section. Click "Login" from bottom menu.

Please sign in

Create Account Recover Password Sign in with LinkedIn

Enter Your Email: